Although TNF-α is also associated with the pathogenesis of diabetic retinopathy [121], TNF-α antagonist, etanercept, adalimumab, and infliximab fail to improve refractory DME [122,123]. The gene discussed is TNF; the disease is diabetic retinopathy.